Search Follow us

Newron Pharmaceuticals (NWRN)

Business description

Newron is a CNS-focused biotech. Xadago (partnered with Zambon, US WorldMeds, Meiji Seika, Sequirus) for PD has been launched in Europe and the US. Other pipeline assets include Sarizotan (Phase III for RS) and Evenamide (Phase II for schizophrenia).

Stock data

Market cap.CHF150.8m
Last closeCHF8.45
High / Low (52 weeks)CHF14.2 / CHF8.2
Stock market listingSW
Forecast net cash (€m)47.9
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(4.5)(35.1)(36.9)
Relative *(3)(33.9)(33.1)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acacia Pharma Acarix
Acerus Pharmaceuticals Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
ADL Bionatur Solutions Adocia
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Antibe Therapeutics Aratana Therapeutics
Ardea Biosciences Ardelyx
Arena Pharmaceuticals arGEN-X
Argos Therapeutics Ariad Pharmaceuticals
Arix Bioscience Ark Therapeutics Group
ArQule Array BioPharma
Arrowhead Research Corporation Ascendis Pharma
ASIT Biotech ASLAN Pharmaceuticals
Astex Pharmaceuticals Athersys
Atossa Genetics Auris Medical
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Avivagen Balda
Basilea Pharmaceutica Bavarian Nordic
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLargo BioLight Life Sciences
BioLineRx BiondVax Pharmaceuticals
Bionomics Bionor Pharma
BioPorto Diagnostics Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
Bonesupport BrainStorm Cell Therapeutics
Brighter BTG
C4X Discovery Holdings Caladrius Biosciences
Can-Fite BioPharma CannTrust Holdings
Cantargia Capstone Therapeutics
Carmat CASI Pharmaceuticals
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clal Biotechnology Industries
Clavis Pharma Cleveland BioLabs
Clinigen Group Clinuvel
CO.DON CollPlant Holdings
Consort Medical Corium International
Crescendo Crossject
CSL Curetis NV
Curis Cytori Therapeutics
Cytos Biotechnology CytRx Corporation
DBV Technologies Dechra Pharmaceuticals
Deinove Delcath Systems
Deltex Medical Derma Sciences
Destiny Pharma DiaSorin
Diaxonhit e-Therapeutics
Egalet Corporation EKF Diagnostics
Elbit Medical Technologies Ellex Medical Lasers
Emergent BioSolutions Endocyte
Epigenomics Erytech Pharma
Esperion Therapeutics Evotec
Exact Sciences Exelixis
EyeGate Pharmaceuticals Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Heat Biologics Inc. Heidelberg Pharma
Herantis Pharma Horizon Discovery
Hutchison China MediTech Hybrigenics
iCo Therapeutics Idenix
Immune Pharmaceuticals Immunicum
Immunodiagnostic Systems Holdings Immunovia
ImmuPharma Immutep
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
InMed Pharmaceuticals Innate Pharma
Insmed Intec Pharma
International Stem Cell Invion
Ion Beam Applications Ipsogen
Iridex Ironwood Pharmaceuticals
Islet Sciences Ixico
Japan Tobacco KaloBios Pharmaceuticals
Kane Biotech Karolinska Development
Kazia Therapeutics Keryx Biopharmaceuticals
Kiadis Pharma Laboratorios Farmacéuticos ROVI
LCA-Vision LeMaitre Vascular
Lifeline Scientific LifeWatch
Ligand Pharmaceuticals Lipocine
Lombard Medical Technologies MagForce
Mast Therapeutics Medcom Tech
Medicago MediciNova
Medicure Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene MGC Pharmaceuticals
Midatech Pharma MISSION Therapeutics
Molecular Partners MolMed
Mologen Momenta Pharmaceuticals
MorphoSys Nanobiotix
Nanosonics Navidea Biopharmaceuticals
Nektar Therapeutics NeoStem
Neovacs NetScientific
NeuroVive Pharmaceutical Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novacyt
NPS Pharmaceuticals Nuevolution
Ocata Therapeutics Omega Diagnostics Group
Omeros Corporation OncoGenex Pharmaceuticals
Oncology Venture Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Orgenesis Oryzon Genomics
OSE Immunotherapeutics Ossur
OvaScience OWL
Oxford BioMedica Pacific Edge
Paion Paladin Labs
Patheon PDL BioPharma
Pharmacyclics PharmaMar
Pharmaxis Pharming Group
Photocure Phylogica
Pixium Vision Pluristem Therapeutics
Prescient Therapeutics Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals Race Oncology
RedHill Biopharma Regeneus
Relmada Therapeutics ReNeuron Group
Resverlogix REVA Medical
Rovi RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Sierra Oncology Silence Therapeutics
Simavita Sinclair Pharma
Sirtex Medical Skyepharma
Smith & Nephew Sobi
Sosei Group Corporation Source Bioscience
SQI Diagnostics Stallergenes
StemCells Stentys
Stratec Biomedical Sucampo Pharmaceuticals
Sunesis Pharmaceuticals Surgical Innovations
Sygnis SymBio Pharmaceuticals
Synairgen Synergy Health
Synta Pharmaceuticals T‐cell cancer therapies
Targovax TearLab Corp
Tekmira Telix Pharmaceuticals
TESARO Theraclion
Therapix Biosciences Threshold Pharmaceuticals
ThromboGenics TiGenix
Tissue Regenix Tissue Therapies
Titan Pharmaceuticals Tonix Pharmaceuticals
Topotarget Touchstone Innovations
Transgene Trillium Therapeutics
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Xbrane Biopharma
Xencor Zafgen
Zealand Pharma Ziopharm Oncology

Company news

Newron Pharmaceuticals Announces Shareholders Accepted All Motions at the AGM 2018

Tue, 27 Mar 2018 10:52:30 GMT

Newron Pharmaceuticals SpA Announces Change in the Board of Directors

Thu, 08 Feb 2018 18:33:45 GMT

Newron Pharmaceuticals Announces Expansion of STARS Study to Include Patients ...

Wed, 17 May 2017 04:52:30 GMT

Newron Pharmaceuticals to Present at the 20th Annual BIO CEO & Investor ...

Tue, 06 Feb 2018 12:00:00 GMT

Newron Pharmaceuticals Supports Rett Syndrome Awareness Month

Mon, 24 Oct 2016 14:00:33 GMT

Y/E Dec Revenue (€m) EBITDA (€m) PBT (€m) EPS (c) P/E (x) P/CF (x)
2016A 6.7 (15.3) (15.2) (103.69) N/A N/A
2017A 13.4 (4.3) (5.3) (32.32) N/A N/A
2018E 5.6 (24.7) (24.5) (137.90) N/A N/A
2019E 10.7 (28.3) (28.2) (158.27) N/A N/A

Last updated on 12/09/2018

Investment summary

Newron continued to made steady progress in H118. A fuller debrief of pipeline assets including sarizotan (Rett syndrome) and Evenamide (schizophrenia) will take place at the R&D day in NYC, scheduled for 31 October. Royalty income from sales of Xadago (Parkinson’s disease, PD) rose by 54% to €2m, driven mainly by increased sales in the EU and Switzerland. However, the US sales contribution remained small (launched by partner US WorldMeds in H217). In H118 Newron reported an operating loss of €7.6m (vs a profit of €2.3m in H117 due to a €10.3m one-time milestone payment in the period), and revised cash and financial investments of €50.6m at July 2018 should enable funding to key value inflection points in 2020. We value Newron at CHF788m.

Last updated on 11/10/2018

Industry outlook

Parkinson's disease is a growing market. Xadago could have a unique position, with once-a-day dosing and a clean safety profile.

Last updated on 28/09/2018

Key management

Stefan Weber, CEO
Marco Caremi, Executive VP of Business Development

Company address

Newron Pharmaceuticals SpA
via Ludovico Ariosto 21
Bresso (Mi)
20091
Italy
+39 02 610 3461
View website